20.36

9.55% -2.15

After Hours: 20.34 -0.02 -0.10%

Immunovant Inc (IMVT)

Overview News Price History Option Chain Financials Why IMVT Down? Discussions Forecast

Immunovant Inc stock is traded at $20.36, with a volume of 2.68M. It is down -9.55% in the last 24 hours and down -17.34% over the past month. Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Previous Close:

$22.51

Open:

$23

24h Volume:

2.68M

Relative Volume:

2.62

Market Cap:

$3.46B

Revenue:

Net Income/Loss:

$-323.01M

P/E Ratio:

-9.1712

EPS:

-2.22

Net Cash Flow:

$-272.30M

1W Performance:

-7.75%

1M Performance:

-17.34%

6M Performance:

-26.89%

1Y Performance:

-44.13%

1-Day Range:

$20.21

$23.11

1-Week Range:

$20.21

$23.11

52-Week Range:

$20.21

$39.55

Immunovant Inc Stock (IMVT) Company Profile

Name

Immunovant Inc

Sector

Healthcare (1177)

Industry

Biotechnology (679)

Phone

917-580-3099

Address

320 WEST 37TH STREET, NEW YORK, NY

Employee

207

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IMVT's Discussions on Twitter

Compare IMVT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IMVT Immunovant Inc	20.36	3.46B	0	-323.01M	-272.30M	-2.22
VRTX Vertex Pharmaceuticals Inc	481.16	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	722.07	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	657.97	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	278.25	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	119.94	28.75B	3.30B	-501.07M	1.03B	-2.1146

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Oct-10-24	Resumed	Raymond James	Outperform
Oct-09-24	Reiterated	Oppenheimer	Outperform
Mar-28-24	Initiated	Oppenheimer	Outperform
Mar-13-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	JP Morgan	Overweight
Feb-15-24	Initiated	Wolfe Research	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-13-23	Upgrade	UBS	Neutral → Buy
Sep-26-23	Upgrade	Raymond James	Mkt Perform → Outperform
May-01-23	Initiated	BofA Securities	Buy
Apr-25-23	Initiated	Citigroup	Buy
Mar-31-23	Initiated	Piper Sandler	Overweight
Mar-30-23	Initiated	Stifel	Buy
Feb-15-23	Initiated	Cantor Fitzgerald	Overweight
Feb-13-23	Upgrade	Guggenheim	Neutral → Buy
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Sep-26-22	Downgrade	UBS	Buy → Neutral
Dec-08-21	Initiated	Wells Fargo	Equal Weight
Aug-03-21	Downgrade	Robert W. Baird	Outperform → Neutral
Aug-02-21	Downgrade	Credit Suisse	Neutral → Underperform
Jun-01-21	Downgrade	Guggenheim	Buy → Neutral
Jun-01-21	Downgrade	Stifel	Buy → Hold
Oct-28-20	Initiated	UBS	Buy
Oct-12-20	Initiated	Guggenheim	Buy
Oct-08-20	Initiated	Stifel	Buy
Oct-02-20	Initiated	Credit Suisse	Outperform
Aug-26-20	Reiterated	H.C. Wainwright	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Jul-29-20	Initiated	H.C. Wainwright	Buy
Feb-24-20	Initiated	SVB Leerink	Outperform

View All

Immunovant Inc Stock (IMVT) Latest News

Feb 06, 2025

Immunovant Reports Progress Amid Increased R&D Costs - TipRanks

Feb 06, 2025

Immunovant (NASDAQ:IMVT) Sets New 1-Year LowHere's What Happened - MarketBeat

Feb 06, 2025

Immunovant's Fiscal Q3 Loss Widens -February 06, 2025 at 07:40 am EST - Marketscreener.com

Feb 06, 2025

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 - The Manila Times

Feb 06, 2025

ForexTV | Small Business Resources - ForexTV.com

Feb 06, 2025

Immunovant's Massive $825M War Chest Fuels Race for Breakthrough Autoimmune Treatments - StockTitan

Feb 06, 2025

Feb 05, 2025

Investor’s Toolkit: Key Ratios for Assessing Immunovant Inc (IMVT)’s Performance - The Dwinnex

Feb 05, 2025

Feb 04, 2025